The study of anti-idiotype antibody and antinuclear antibodies (ANA) in people receiving three doses of the COVID-19 vaccine

Abstract

Introduction: The anti-idiotype network was introduced in 1974 by Niels Jerne. One of the factors that reduces the effectiveness of the vaccines is the anti-idiotype network. It should be noted that the Anti-idiotype of the antibody has the ability to bind to the receptors of the body cells to which the antigen of the first antibody binds; this causes pathological complications, especially after a longer period of time. In this study, we aim to be the first to study the presence of Anti-idiotype antibodies and ANA in people who have received three doses of the COVID-19 vaccine and check that at least 4 months have passed since the injection of their third dose. Materials and Methods: This study was conducted on 180 people and measuring amount of Anti-RBD Anti-idiotype, Anti-Nuclear Antibody (IgG antibodies against RNP, sm RNP, smSSB/La, SSA/Ro, scl 70, centromere B, Jo1, and dsDNA antigens) and SARS-COV-Anti IgG RBD in serum by ELISA methods. Results: In the measurement of Anti-RBD Anti-idiotype, it was found that 14 people (7.7%) of the studied subjects had Anti-idiotype antibodies and 166 (92.3%) lacked this antibody. It was found that five of the studied subjects (2.7%) had positive values for ANA (above 50 RU/ML; in 175 people (97.3), the ANA value was negative (less than 50 RU/ML). In the examination of the results related to the measurement of the quantitative amount of SARS-COV-Anti IgG RBD, it was found that all 180 people included in the study (100%) had a detectable titer of Anti-RBD antibody. Conclusion: Many studies have shown an association between autoimmune diseases and SARS-COV-2 and MERS-CoV. Nevertheless, no studies have investigated autoantibodies in people who have injected three doses of the COVID-19 vaccine. further studies are warranted to confirm and find the causes of this difference.